Free Trial

Opus Genetics (IRD) Competitors

Opus Genetics logo
$1.18 -0.03 (-2.48%)
Closing price 04:00 PM Eastern
Extended Trading
$1.20 +0.02 (+1.69%)
As of 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IRD vs. ZYBT, ACB, SCPH, INZY, VOR, ANNX, AARD, NBTX, IMMP, and SOPH

Should you be buying Opus Genetics stock or one of its competitors? The main competitors of Opus Genetics include Zhengye Biotechnology (ZYBT), Aurora Cannabis (ACB), scPharmaceuticals (SCPH), Inozyme Pharma (INZY), Vor Biopharma (VOR), Annexon (ANNX), Aardvark Therapeutics (AARD), Nanobiotix (NBTX), Prima BioMed (IMMP), and SOPHiA GENETICS (SOPH). These companies are all part of the "pharmaceutical products" industry.

Opus Genetics vs. Its Competitors

Opus Genetics (NASDAQ:IRD) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

Opus Genetics currently has a consensus price target of $7.33, indicating a potential upside of 521.47%. Given Opus Genetics' stronger consensus rating and higher probable upside, analysts plainly believe Opus Genetics is more favorable than Zhengye Biotechnology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Opus Genetics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Zhengye Biotechnology
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

15.0% of Opus Genetics shares are held by institutional investors. 6.6% of Opus Genetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Zhengye Biotechnology has a net margin of 0.00% compared to Opus Genetics' net margin of -429.42%. Zhengye Biotechnology's return on equity of 0.00% beat Opus Genetics' return on equity.

Company Net Margins Return on Equity Return on Assets
Opus Genetics-429.42% -283.28% -144.32%
Zhengye Biotechnology N/A N/A N/A

In the previous week, Opus Genetics had 2 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 3 mentions for Opus Genetics and 1 mentions for Zhengye Biotechnology. Zhengye Biotechnology's average media sentiment score of 1.87 beat Opus Genetics' score of 0.62 indicating that Zhengye Biotechnology is being referred to more favorably in the news media.

Company Overall Sentiment
Opus Genetics Positive
Zhengye Biotechnology Very Positive

Zhengye Biotechnology has higher revenue and earnings than Opus Genetics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Opus Genetics$10.99M6.41-$57.53M-$2.10-0.56
Zhengye Biotechnology$25.53M10.25$1.55MN/AN/A

Summary

Zhengye Biotechnology beats Opus Genetics on 7 of the 13 factors compared between the two stocks.

Get Opus Genetics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IRD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IRD vs. The Competition

MetricOpus GeneticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$72.19M$3.07B$5.70B$9.51B
Dividend YieldN/A2.36%4.69%4.01%
P/E Ratio-0.5621.0428.0720.05
Price / Sales6.41284.46448.5799.42
Price / CashN/A42.7636.2258.56
Price / Book5.628.378.665.87
Net Income-$57.53M-$55.19M$3.25B$258.55M
7 Day Performance4.42%5.89%4.20%2.23%
1 Month Performance21.62%17.63%10.82%12.76%
1 Year PerformanceN/A5.09%34.70%19.36%

Opus Genetics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IRD
Opus Genetics
1.6496 of 5 stars
$1.18
-2.5%
$7.33
+521.5%
N/A$72.19M$10.99M-0.5614
ZYBT
Zhengye Biotechnology
N/A$5.69
flat
N/AN/A$268.38M$25.53M0.00278Positive News
Gap Up
ACB
Aurora Cannabis
0.2778 of 5 stars
$4.70
+3.8%
N/A-16.5%$264.36M$343.29M42.731,130
SCPH
scPharmaceuticals
4.3958 of 5 stars
$5.13
+3.8%
$14.00
+172.9%
+20.7%$260.79M$41.98M-2.6930News Coverage
INZY
Inozyme Pharma
2.7992 of 5 stars
$4.00
flat
$11.75
+193.8%
N/A$258.25MN/A-2.3750
VOR
Vor Biopharma
3.8804 of 5 stars
$2.05
-7.2%
$5.63
+174.6%
+129.7%$256.17MN/A-1.24140
ANNX
Annexon
2.456 of 5 stars
$2.47
+6.5%
$12.50
+406.1%
-58.1%$254.54MN/A-2.0960
AARD
Aardvark Therapeutics
N/A$12.00
+3.3%
$33.00
+175.0%
N/A$252.11MN/A0.0018
NBTX
Nanobiotix
1.6198 of 5 stars
$5.11
-3.6%
$8.00
+56.6%
+22.0%$249.81M$39.18M0.00100News Coverage
Gap Up
IMMP
Prima BioMed
1.4938 of 5 stars
$1.71
+0.6%
$7.00
+309.4%
-19.0%$248.27MN/A0.002,021News Coverage
Positive News
Upcoming Earnings
SOPH
SOPHiA GENETICS
2.5693 of 5 stars
$3.49
-6.2%
$7.00
+100.6%
-21.9%$248.08M$65.17M-3.49520

Related Companies and Tools


This page (NASDAQ:IRD) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners